A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Brief description of study

To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.

Clinical Study Identifier: NCT02974725

Start Over

Novartis Investigative Site

Villejuif Cedex, France

9.91miles

View all locations

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up now »

Powered by